Drug Trial Radar · NCT05827653
MAD Study of NX210c
Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Dec 5, 2022
Primary completion
Apr 29, 2023
Study completion Oct 2, 2023
Sponsor
- Lead sponsor
- Axoltis PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Centre for Human Drug Research, Netherlands
- First posted
- Apr 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.
Conditions
- Healthy Elderly
Interventions
NX210cDrug
3 times a week, for 28 days
PlaceboDrug
3 times a week, for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity and incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs)Time frame: Up to 16 days after last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Human Drug Research
Leiden, South Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.